{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:46:25Z","timestamp":1791315985605,"version":"4.3.1"},"reference-count":67,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,12,11]],"date-time":"2003-12-11T00:00:00Z","timestamp":1071100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Concern about late adverse effects of cranial radiotherapy (XRT) has led to alternative approaches to eliminate leukaemia from the central nervous system (CNS) in childhood acute lymphoblastic leukaemia (ALL). The Medical Research Council UKALL XI trial recruited 2090 children with ALL between 1990 and 1997. Median follow\u2010up is 7\u2003years 9\u2003months; event\u2010free survival (EFS) and overall survival were 63\u00b71% and 84\u00b76%, respectively, at 5\u2003years and 59\u00b78% and 79\u00b74% at 10\u2003years. The isolated CNS relapse rate was 7\u00b70% at 10\u2003years. Patients were randomized for CNS\u2010directed therapy within white blood cell (WBC) groups. For WBC &lt;50\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\/l, high\u2010dose intravenous methotrexate (HDMTX) (6\u20138\u2003g\/m<jats:sup>2<\/jats:sup>) with intrathecal methotrexate (ITMTX) was compared with ITMTX alone, and was significantly better at preventing isolated and combined CNS relapse, but non\u2010CNS relapses were similar. There was no significant difference in EFS at 10\u2003years, 64\u00b71% [95% confidence interval (CI) 60\u00b74\u201367\u00b78] with HDMTX plus ITMTX, and 63\u00b70% (95% CI 59\u00b75\u201366\u00b75) with ITMTX alone. For WBC \u226550\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\/l, HDMTX with ITMTX was compared with XRT and a short course of ITMTX. CNS relapses were significantly fewer with XRT, but there was a non\u2010significant increase in non\u2010CNS relapses. EFS was not significantly different, being 55\u00b72% (95% CI 47\u00b78\u201362\u00b76) at 10\u2003years with XRT and 52\u00b71% (95% CI 44\u00b78\u201359\u00b74) with HDMTX plus ITMTX.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2003.04738.x","type":"journal-article","created":{"date-parts":[[2004,12,21]],"date-time":"2004-12-21T07:33:25Z","timestamp":1103614405000},"page":"33-46","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk\u2010stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172)"],"prefix":"10.1111","volume":"124","author":[{"given":"Frank G. H.","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lilleyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Kinsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osborn B.","family":"Eden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the UK Medical Research Council Working Party on Childhood Leukaemia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,12,11]]},"reference":[{"key":"e_1_2_19_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.2.202"},{"key":"e_1_2_19_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950100412"},{"key":"e_1_2_19_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.5.317"},{"key":"e_1_2_19_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880019009033410"},{"key":"e_1_2_19_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.6.1012"},{"key":"e_1_2_19_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870701)60:1<5::AID-CNCR2820600103>3.0.CO;2-D"},{"key":"e_1_2_19_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90269-J"},{"key":"e_1_2_19_9_1","first-page":"2024","article-title":"Dexamethasone decreases central nervous system (CNS) relapse and improves event\u2010free survival (EFS) in lower risk acute lymphoblastic leukemia (ALL)","author":"Bostrom B.","year":"1998","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"e_1_2_19_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03647.x"},{"key":"e_1_2_19_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.73.2.136"},{"key":"e_1_2_19_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91246-9"},{"key":"e_1_2_19_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7610.1988.tb00757.x"},{"key":"e_1_2_19_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199809000-00007"},{"key":"e_1_2_19_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90997-H"},{"key":"e_1_2_19_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb04415.x"},{"key":"e_1_2_19_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197008)26:2<404::AID-CNCR2820260222>3.0.CO;2-I"},{"key":"e_1_2_19_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198303033080902"},{"key":"e_1_2_19_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199702)28:2<98::AID-MPO3>3.0.CO;2-N"},{"key":"e_1_2_19_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401939"},{"key":"e_1_2_19_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401093"},{"key":"e_1_2_19_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401704"},{"key":"e_1_2_19_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02668.x"},{"key":"e_1_2_19_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02543.x"},{"key":"e_1_2_19_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02643.x"},{"key":"e_1_2_19_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0308-2261(78)80008-3"},{"key":"e_1_2_19_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92997-1"},{"key":"e_1_2_19_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950190411"},{"key":"e_1_2_19_29_1","first-page":"1226","article-title":"Intensive treatment of children with acute lymphoblastic leukaemia according to ALL\u2010BFM\u201086 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL\u20107 (1988\u20131991)","volume":"94","author":"Kamps W.A.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_19_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2848"},{"key":"e_1_2_19_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880019109028802"},{"key":"e_1_2_19_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199607)27:1<15::AID-MPO4>3.0.CO;2-X"},{"key":"e_1_2_19_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01891.x"},{"key":"e_1_2_19_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.237"},{"key":"e_1_2_19_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880019009033413"},{"key":"e_1_2_19_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.1002914.x"},{"key":"e_1_2_19_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103213241205"},{"key":"e_1_2_19_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(87)90308-7"},{"key":"e_1_2_19_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.9.2770.009k16_2770_2775"},{"key":"e_1_2_19_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5863.381"},{"key":"e_1_2_19_41_1","first-page":"1","article-title":"Intermediate dose methotrexate in childhood acute lymphoblastic leukaemia","volume":"1","author":"Moe P.J.","year":"1984","journal-title":"European Paediatric Haematology & Oncology"},{"key":"e_1_2_19_42_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1200\/JCO.1988.6.2.315","article-title":"Memory function in disease\u2010free survivors of childhood acute lymphoblastic leukemia given CNS prophylaxis with or without 1800 cGy cranial irradiation","volume":"6","author":"Mulhern R.K.","year":"1988","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_19_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.8.1348"},{"key":"e_1_2_19_44_1","first-page":"265","article-title":"Intrathecal methotrexate is sufficient central nervous system prophylaxis for high risk patients with acute lymphoblastic leukemia (ALL) showing a rapid early response to BFM induction chemotherapy","volume":"86","author":"Nachman J.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_19_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.920"},{"key":"e_1_2_19_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91849-3"},{"key":"e_1_2_19_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80208-2"},{"key":"e_1_2_19_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.145"},{"key":"e_1_2_19_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"e_1_2_19_50_1","first-page":"282","article-title":"Dexamethasone is much more potent than prednisolone in the assumed equivalent doses in childhood leukemia","volume":"11","author":"Pieters R.","year":"1992","journal-title":"Proceedings of American Society of Clinical Oncology"},{"key":"e_1_2_19_51_1","first-page":"150","article-title":"Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long\u2010term results of St Jude Total Therapy Study X","volume":"6","author":"Pui C.H.","year":"1992","journal-title":"Leukemia"},{"key":"e_1_2_19_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.5.839"},{"key":"e_1_2_19_53_1","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukaemia patients. Results and conclusions of multicenter trial ALL\u2010BFM 86","volume":"84","author":"Reiter A.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_19_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401065"},{"key":"e_1_2_19_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90733-6"},{"key":"e_1_2_19_56_1","first-page":"314","volume-title":"Acute Leukaemia IV. Prognostic Factors & Treatment Strategies","author":"Schaison G.","year":"1993"},{"key":"e_1_2_19_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401973"},{"key":"e_1_2_19_58_1","first-page":"3310","article-title":"Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL\u2010BFM 90. German\u2010Austrian\u2010Swiss ALL\u2010BFM Study Group","volume":"95","author":"Schrappe M.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_19_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.9.1390"},{"key":"e_1_2_19_60_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880018709141247"},{"key":"e_1_2_19_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<205::AID-CNCR28>3.0.CO;2-7"},{"key":"e_1_2_19_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.389"},{"key":"e_1_2_19_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.520"},{"key":"e_1_2_19_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.66.12.1403"},{"key":"e_1_2_19_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.911"},{"key":"e_1_2_19_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.5.810"},{"key":"e_1_2_19_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3761"},{"key":"e_1_2_19_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1978.124"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2003.04738.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2003.04738.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2003.04738.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T08:03:01Z","timestamp":1697443381000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2003.04738.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,11]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1046\/j.1365-2141.2003.04738.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04738.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,11]]},"assertion":[{"value":"2003-12-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}